hemophagocytosi
engulf
hematopoiet
cell
activ
macrophag
act
outsid
usual
immun
system
regul
hemophagocyt
lymphohistiocytosi
hlh
cover
wide
array
relat
diseas
includ
hlh
autosom
recess
famili
hlh
fhl
famili
erythrophagocyt
lymphohistiocytosi
viralassoci
hemophagocyt
syndrom
autoimmuneassoci
macrophag
activ
syndrom
ma
disord
featur
sever
cytopenia
due
uncontrol
hemophagocytosi
laboratori
sign
clinic
symptom
result
disord
immun
regul
cytokin
storm
term
primari
hlh
refer
underli
genet
abnorm
caus
disord
wherea
secondari
hlh
indic
disord
secondari
underli
condit
infect
autoimmunerheumatolog
malign
metabol
condit
purpos
review
fhl
indic
case
primari
genet
caus
secondari
hlh
refer
case
secondari
infect
malign
metabol
disord
ma
refer
case
associ
autoimmun
diseas
much
learn
hlh
year
sinc
first
discov
one
earliest
descript
diseas
scott
describ
disord
featur
erythrophagocytosi
prolifer
histiocyt
lymphoreticular
system
call
histiocyt
medullari
reticulosi
hmr
later
classifi
among
malign
histiocytosi
later
famili
form
hlh
fhl
fulli
describ
farquhar
case
two
sibl
succumb
hlh
later
anoth
sibl
famili
present
risdal
among
first
describ
viral
associ
hlh
propos
condit
call
virusassoci
hlh
distinct
malign
year
sinc
research
recogn
wide
scope
diseas
fact
infect
often
trigger
primari
secondari
hlh
regardless
caus
physiolog
hlh
character
defect
cytotox
cell
function
coupl
unbridl
macrophag
activ
lead
excess
cytokin
product
subsequ
immun
dysregul
tissu
damag
left
untreat
dysregul
inflammatori
respons
caus
sever
neutropenia
patient
often
die
bacteri
fungal
infect
condit
carri
high
morbid
longterm
surviv
estim
low
median
surviv
without
treatment
estim
diagnosi
fhl
secondari
hlh
base
number
clinic
sign
laboratori
find
due
rel
nonspecif
natur
clinic
sign
symptom
signific
overlap
ill
diagnosi
often
delay
offici
diagnosi
hlh
establish
histiocyt
societi
base
fulfil
one
follow
criteria
clinic
laboratori
find
readili
link
pathophysiolog
hlh
fever
result
high
il
level
splenomegali
direct
result
infiltr
lymphocyt
macrophag
cytopenia
explain
high
concentr
tumor
necrosi
factor
tnf
interferon
ifn
well
direct
hemophagocytosi
high
triglycerid
secondari
decreas
lipoprotein
lipas
activ
initi
increas
level
elev
ferritin
demonstr
sensit
specif
ferritin
believ
accumul
antiinflammatori
process
macrophag
scaveng
heme
via
receptor
high
concentr
solubl
receptor
produc
activ
summari
clinic
laboratori
find
provid
tabl
coagulopathi
promin
featur
hlh
low
fibrinogen
found
major
patient
coagul
studi
demonstr
normal
factor
v
viii
level
absenc
fibrin
split
product
find
provid
evid
dissemin
intravascular
coagul
diagnosi
may
overlap
hlh
due
share
find
thrombocytopenia
believ
macrophag
may
secret
plasminogen
activ
acceler
convers
plasminogen
plasmin
subsequ
degrad
fibrinogen
fibrin
split
product
may
phagocyt
macrophag
reticuloendotheli
system
given
normal
coagul
factor
measur
hlh
liver
failur
often
present
relat
coagulopathi
hepatomegali
elev
transaminas
bilirubin
believ
direct
result
organ
infiltr
lymphocyt
iron
despit
fact
hemophagocytosi
promin
featur
name
diseas
rare
found
present
secondari
case
may
visibl
late
diseas
progress
bone
marrow
biopsi
perform
earli
cours
secondari
diseas
may
normal
demonstr
nonspecif
find
increas
decreas
unilineag
multilineag
hematopoiesi
repeat
studi
may
necessari
show
find
fhl
hand
may
demonstr
promin
hemophagocytosi
start
immunohistochem
stain
may
use
upregul
receptor
facilit
case
cerebrospin
fluid
obtain
pleocytosi
sometim
note
lymphocyt
histiocyt
increas
protein
level
microscop
review
spun
cerebrospin
fluid
may
demonstr
mani
laboratori
test
readili
avail
evalu
receptor
nkcell
activ
may
requir
send
specimen
special
refer
laboratori
may
time
option
clinic
diagnosi
avail
comparison
may
use
distinguish
bacteri
sepsi
viral
infect
hlh
use
criteria
pgml
pgml
sensit
specif
diagnos
hlh
addit
measur
plasma
level
receptor
hemoglobinhaptoglobin
complex
may
also
help
distinguish
hlh
pure
infecti
flow
cytometri
may
use
identifi
quantifi
level
sever
use
marker
involv
pathophysiolog
hlh
rapid
flow
cytometr
analysi
intracellular
xlink
inhibitor
apoptosi
protein
xiap
develop
detect
xlink
lymphoprolif
diseas
carrier
state
also
proven
use
follow
bone
marrow
transplant
monitor
prospect
evalu
degranul
assay
found
use
differenti
diagnosi
fhl
may
serv
use
surrog
marker
reduc
absent
nkcell
cytotox
tcell
activ
use
assay
surfac
upregul
nkcell
cytotox
tlymphocyt
larg
cohort
patient
evalu
hlh
vast
major
patient
fhl
subtyp
griscelli
syndrom
gs
type
syndrom
ch
abnorm
rest
nkcell
degranul
nkcell
degranul
found
normal
major
patient
fhl
type
xlink
lymphoprolif
diseas
instead
patient
found
diminish
intracellular
sap
slam
signal
lymphocyt
activ
molecul
associ
protein
xiap
perforin
express
patient
secondari
hlh
abnorm
nkcell
degranul
thu
degranul
assay
may
help
speed
diagnosi
hlh
allow
treatment
begin
degranul
may
associ
specif
type
fhl
missens
mutat
lead
decreas
lymphocyt
stabil
syntaxin
bind
protein
syntaxin
protein
would
normal
involv
regul
vesicl
transport
plasma
membran
key
pathophysiolog
flow
cytometri
perforin
stain
cytotox
lymphocyt
includ
nkcell
tcell
tcell
seem
use
quick
reliabl
marker
perforin
gene
mutat
seen
hlh
studi
eleven
unrel
hlh
patient
famili
member
four
seven
patient
fhl
show
lack
intracellular
perforin
cytotox
cell
type
correspond
mutat
perforin
gene
parent
patient
also
abnorm
perforin
stain
indic
carrier
state
perforin
mutat
evalu
cytotox
tcell
three
patient
fhl
demonstr
normal
percentag
perforin
stain
cytotox
tcell
four
patient
viru
ebv
associ
secondari
hlh
depress
number
nkcell
increas
tcell
perforin
flow
cytometri
studi
proven
rapid
use
modal
reliabl
diagnos
hlh
shorten
time
difficult
assess
true
epidemiolog
hlh
diseas
studi
extens
sweden
incid
fhl
estim
live
overal
estim
hlh
children
year
old
across
ethnic
race
approxim
larg
seri
describ
hong
kong
taiwan
howev
worldwid
incid
fhl
unknown
even
less
epidemiolog
data
avail
regard
acquir
hlh
larg
believ
condit
underrecogn
hemophagocytosi
often
patholog
evid
autopsi
famili
type
usual
diagnos
childhood
secondari
hlh
occur
age
sporad
famili
case
hlh
initi
infecti
caus
howev
import
distinguish
primari
genet
case
versu
secondari
treatment
underli
condit
may
attempt
latter
patient
meet
criteria
test
precipit
infect
includ
cultur
blood
urin
chest
radiographi
screen
ebv
cytomegaloviru
parvoviru
human
immunodefici
viru
hiv
human
herp
throat
rectal
swab
viral
cultur
may
also
prove
use
hlh
also
link
hivassoci
infect
pneumocystosi
histoplasmosi
appropri
screen
infect
patient
consid
also
recommend
patient
travel
histori
screen
relev
possibl
role
infecti
diseas
caus
hlh
first
elucid
case
seri
describ
renal
transplant
patient
viralassoci
hlh
viralassoci
hemophagocyt
syndrom
ebv
dna
deoxyribonucl
acid
viru
member
herpesvirida
famili
consist
report
viru
associ
major
ebvassoci
hlh
case
report
asia
limit
inform
incid
elsewher
world
japanes
studi
estim
annual
incid
hlh
person
per
year
case
secondari
onethird
secondari
case
relat
ebv
lead
estim
annual
incid
case
ebvassoci
hlh
per
million
person
theoriz
higher
rate
ebvassoci
hlh
asian
countri
may
due
pathogen
strain
sever
studi
perform
sequenc
analysi
ebv
nuclear
antigen
gene
latent
membran
studi
demonstr
singl
substrain
ebv
link
hlh
appear
new
infect
well
reactiv
latent
ebv
infect
may
predispos
individu
hlh
quantit
determin
ebv
genom
copi
number
peripher
blood
may
use
predict
prognosi
effect
interestingli
male
patient
ebvassoci
hlh
may
mutat
gene
tradit
associ
xlink
lymphoprolif
syndrom
xlp
xlp
character
immunodefici
ebv
japanes
studi
perform
genet
analysi
gene
male
patient
present
sever
ebvassoci
ill
includ
fulmin
infecti
mononucleosi
ebvposit
lymphoma
chronic
ebv
infect
find
mutat
quarter
patient
given
strong
associ
recommend
male
patient
ebvassoci
hlh
screen
fulmin
infecti
mononucleosi
may
overlap
ebvassoci
hlh
higher
viral
load
seen
ebvassoci
commonli
report
well
defin
ebv
mani
virus
may
associ
hlh
best
organ
dna
rna
ribonucl
acid
subsequ
viru
famili
list
tabl
year
risdal
et
describ
possibl
viral
etiolog
hlh
group
discov
link
bacteria
well
common
bacteri
infect
associ
hlh
given
tabl
first
bacteriaassoci
hlh
case
identifi
connect
protozoan
parasit
fungal
infect
far
behind
numer
report
parasiteassoci
hlh
also
report
common
comprehens
discuss
zoonos
associ
hlh
present
cascio
et
common
protozoan
associ
hlh
present
tabl
fungal
organ
may
caus
hlh
either
primari
caus
associ
immunosuppress
hiv
infect
common
fungal
organ
associ
hlh
list
tabl
malign
associ
signific
percentag
secondari
hlh
case
among
case
hematolog
malign
preval
hematolog
disord
best
classifi
accord
cell
type
children
hlh
commonli
associ
acut
blymphoblast
cytokin
releas
malign
mainli
believ
incit
factor
malignancyassoci
hlh
overview
malign
associ
hlh
given
tabl
ad
complic
understand
hlh
observ
hlh
seen
first
week
follow
hematopoiet
stemcel
transplant
hsct
malign
posttranspl
hlh
particularli
difficult
diagnos
clinic
laboratori
sign
overlap
recov
bone
marrow
hlh
well
known
occur
set
variou
autoimmun
disord
lupu
erythematosu
one
common
condit
ma
seriou
often
fatal
complic
children
system
juvenil
idiopath
arthriti
sjia
adult
still
ma
gener
consid
type
secondari
hlh
children
sjia
may
heterozyg
express
gene
associ
ma
often
present
sjia
children
shortli
initi
nonsteroid
antiinflammatori
drug
rheumatolog
condit
associ
hlh
includ
polyarter
nodosa
mix
connect
diseas
pulmonari
sarcoidosi
system
sclerosi
ma
consid
uniqu
type
hlh
detail
literatur
elsewher
genet
caus
hlh
divid
two
group
fhl
immun
defici
ch
gs
xlp
fhl
first
describ
farquhar
hlh
describ
tragic
case
two
sibl
develop
rapidli
fatal
ill
fever
diarrhea
vomit
week
age
term
ill
famili
hemophagocyt
reticulosi
children
hepatosplenomegali
without
lymphadenopathi
also
pancytopenia
infant
die
autopsi
histiocyt
prolifer
activ
hemophagocytosi
readili
appar
lymph
node
spleen
liver
kidney
third
child
famili
unaffect
fourth
affect
report
farquhar
numer
case
variou
name
report
medic
literatur
includ
famili
erythrophagocyt
lymphohistiocytosi
famili
lymphohistiocytosi
gener
lymphohistiocyt
infiltr
name
high
percentag
fhl
case
associ
parent
immun
defici
syndrom
associ
hlh
ch
gs
abnorm
cellular
granul
ch
typic
featur
albin
recurr
pyogen
infect
due
defici
white
blood
cell
decreas
chemotaxi
contain
giant
lysosom
inclus
bodi
gs
also
featur
albinismhypopigment
neutrophil
dysfunct
xlp
associ
mark
vulner
ebv
infect
subsequ
viralassoci
hlh
immun
system
predispos
lymphoma
patient
may
develop
ebvhlh
rare
condit
condit
associ
predisposit
hlh
report
literatur
includ
common
variabl
renal
transplant
name
understand
defect
function
sever
type
immun
cell
hlh
greatli
enhanc
knowledg
normal
physiolog
cytotox
cell
sever
cell
type
involv
pathophysiolog
hlh
includ
macrophag
nkcell
cytotox
tlymphocyt
macrophag
typic
serv
antigen
present
cell
present
foreign
antigen
lymphocyt
either
direct
destruct
antibodi
develop
variou
form
hlh
macrophag
becom
activ
secret
cytokin
cytokin
turn
caus
organ
damag
excret
excess
amount
nkcell
directli
destroy
damag
infect
cell
independ
major
histocompat
complex
mhc
cytotox
tlymphocyt
similar
nkcell
kill
autolog
cell
carri
foreign
antigen
associ
mhc
class
altern
theori
propos
ineffect
antigen
remov
result
ongo
immun
stimul
inappropri
defect
nkcell
function
may
vari
within
variou
type
hlh
indic
sever
aspect
cell
signal
like
involv
nkcell
dysfunct
seen
particular
patient
type
nkcell
defici
complet
absent
nkcell
function
like
need
hematopoiet
cell
patient
ch
associ
high
frequenc
hlh
often
defect
cytotox
tlymphocyteassoci
antigen
secretori
lysosom
move
cell
defici
apoptosi
appear
underli
mechan
behind
least
form
fhl
theori
support
success
etoposid
drug
use
trigger
fhl
syndrom
subclassifi
base
upon
function
protein
anomali
prerequisit
gene
mutat
respons
genet
abnorm
identifi
syndrom
outlin
tabl
gener
form
hlh
associ
infant
young
children
caus
defect
immun
regul
mutat
gene
control
function
cytotox
tlymphocyt
nkcell
older
children
adult
hlh
like
secondari
infect
malign
autoimmun
diseas
rare
famili
case
undetect
adulthood
even
children
defin
genet
caus
hlh
often
secondari
assault
infect
trigger
hlh
keep
twohit
hypothesi
requir
develop
mani
diseas
first
genet
defect
describ
fhl
mutat
perforin
gene
stepp
et
perforin
found
secretori
granul
cytotox
cell
play
import
role
apoptosi
immun
modul
perforin
mutat
caus
major
fhl
case
account
consid
defin
featur
patient
present
later
life
may
residu
perforin
express
patient
present
earli
childhood
usual
perforin
nk
cell
hlh
studi
group
histiocyt
societi
identifi
specif
mutat
within
perforin
gene
demonstr
vari
preval
among
ethnic
group
three
common
mutat
specif
associ
turkish
africanafrican
american
japanes
origin
respect
common
perforin
polymorph
seen
lateonset
fhl
demonstr
lead
dysfunct
detail
discoveri
role
perforin
hlh
lymphoma
immunemedi
diseas
recent
gene
involv
cytotox
granul
exocytosi
demonstr
bear
mutat
case
account
genet
hlh
featur
essenti
role
gene
fusion
cytolyt
granul
involv
fhl
first
describ
feldmann
et
patient
disrupt
mutat
present
younger
age
patient
missens
mutat
older
patient
mark
central
nervou
system
involv
character
mutat
found
almost
exclus
patient
turkishkurdish
gene
mutat
caus
describ
recent
zur
stadt
et
al
also
et
locu
chromosom
code
yet
unknown
gene
protein
involv
develop
account
fewer
case
fhl
approxim
asid
fhl
immun
defici
syndrom
associ
hlh
includ
gs
xlp
group
base
molecular
featur
similar
fhl
molecular
standpoint
gs
character
intracellular
vesicl
content
dock
fusion
defect
character
albin
neutrophil
granul
dysfunct
recurr
infect
xlp
hand
molecularli
distinct
xlp
lack
normal
immun
function
tlymphocyt
rather
neutrophil
granul
defect
genet
defect
associ
condit
present
tabl
gene
express
analysi
mononuclear
cell
patient
variou
genotyp
hlh
demonstr
increas
express
along
clinic
diagnosi
hlh
gene
express
profil
may
use
predict
risk
relaps
respons
treatment
earli
attempt
treat
hlh
includ
vinblastin
vinca
alkaloid
corticosteroid
epipodophyllotoxin
etoposid
teniposid
combin
steroid
show
promis
achiev
prolong
remiss
histiocyt
societi
propos
first
protocol
treatment
hlh
protocol
began
year
genet
marker
fhl
found
time
fhl
defin
affect
sibl
offer
establish
chemotherapi
regimen
epidodophyllotoxin
corticosteroid
conjunct
immunotherapi
cyclosporin
csa
origin
elig
requir
trial
includ
patient
age
year
includ
week
initi
chemotherapi
immunotherapi
attempt
achiev
complet
remiss
follow
continu
therapi
accept
bone
marrow
donor
could
found
first
week
consist
dexamethason
start
dosag
bodi
surfac
area
taper
half
increment
week
week
subsequ
week
taper
concurr
dexamethason
taper
therapi
initi
twice
weekli
first
week
weekli
week
csa
therapi
began
extend
durat
therapi
intrathec
methotrex
includ
select
patient
evid
central
nervou
system
cn
involv
week
puls
dexamethason
given
regular
interv
hsct
recommend
children
suitabl
allogen
donor
support
care
may
includ
intens
care
unit
stay
broadspectrum
antibiot
appropri
cultur
result
avail
microbiolog
surveil
hla
test
patient
famili
anticip
hsct
prophylact
condit
regimen
prior
hsct
includ
busulfan
cyclophosphamid
etoposid
donor
unrel
antithymocyt
globulin
atg
retrospect
review
treatment
protocol
morbid
mortal
patient
longterm
followup
reveal
overal
surviv
respons
therapi
differ
patient
versu
without
famili
histori
overal
surviv
rate
studi
die
receiv
transplant
patient
death
occur
first
year
eight
death
occur
year
therapi
two
progress
diseas
without
avail
hsct
donor
one
could
transplant
due
sever
neurolog
diseas
five
relaps
overal
achiev
complet
remiss
allow
surviv
hsct
given
success
protocol
revis
protocol
call
propos
aim
evalu
revis
initi
continu
therapi
end
goal
hsct
evalu
improv
result
hsct
variou
type
donor
evalu
prognost
import
state
remiss
time
hsct
evalu
longterm
neurolog
sequela
improv
understand
pathophysiolog
hlh
includ
studi
evalu
prognost
valu
nkcell
activ
subtyp
essenti
took
move
cyclosporin
later
regimen
initi
therapi
concurr
dexamethason
dexamethason
dose
intrathec
methotrex
still
includ
select
patient
cn
involv
gener
approach
patient
initi
week
chemotherapi
support
patient
hsct
perform
case
patient
genet
determin
diseas
persist
nongenet
diseas
case
resolv
nongenet
ceas
therapi
unless
relaps
occur
case
hsct
would
undertaken
elig
requir
includ
children
year
old
separ
concurr
studi
undertaken
patient
year
old
ch
gs
protocol
offici
ceas
enrol
end
longterm
outcom
still
evalu
altern
regimen
fhl
first
describ
stephan
et
expand
trial
describ
mahlaoui
et
develop
regimen
base
recognit
tlymphocyt
play
role
patholog
hlh
well
macrophag
discoveri
base
detect
major
histocompat
complex
class
ii
posit
tcell
high
level
solubl
serum
serum
fhl
patient
regimen
featur
combin
atg
corticosteroid
csa
intrathec
methotrex
stephan
studi
evalu
six
patient
success
achiev
remiss
quickli
although
two
patient
die
cn
diseas
expand
studi
regimen
use
treat
consecut
patient
fhl
cours
year
patient
receiv
cours
atg
total
dosag
mgkg
mgkg
vari
sever
diseas
cours
day
methylprednisolon
mgkgday
administ
atg
day
taper
intrathec
methotrex
corticosteroid
given
variou
dosag
determin
patient
age
interv
vari
accord
sever
cn
involv
patient
also
receiv
support
care
fibrinogen
infus
irradi
pack
red
blood
cell
platelet
broad
spectrum
antibiot
intraven
immunoglobulin
also
given
csa
ad
reach
plasma
concentr
ngml
prior
hsct
immedi
advers
effect
atg
rel
minor
present
fever
chill
infus
rapidli
resolv
preclud
treatment
approxim
week
atg
treatment
bacteri
viral
fungal
infect
encount
infect
common
patient
receiv
atg
secondari
treatment
relaps
firstlin
therapi
complet
respons
achiev
evidenc
normal
clinic
biolog
paramet
hsct
perform
patient
avail
hla
ident
donor
patient
without
complet
respons
without
viabl
donor
given
mainten
therapi
overal
efficaci
atg
therapi
achiev
complet
remiss
use
atg
firstlin
treatment
higher
success
rate
patient
achiev
complet
remiss
versu
achiev
complet
remiss
secondlin
atg
treatment
best
outcom
seen
patient
receiv
hsct
shortli
start
atg
treat
incit
infecti
agent
import
treatment
infectionrel
hlh
treat
identifi
organ
alon
enough
case
infectionrel
hlh
treat
aggress
standard
hlh
protocol
except
rule
leishmaniarel
hlh
treat
success
liposom
amphotericin
particular
prognosi
ebvassoci
case
improv
dramat
chemotherapi
immun
modifi
agent
multivari
analysi
patient
regimen
consist
corticosteroid
alon
intraven
immunoglobulin
alon
csa
alon
combin
treatment
without
etoposid
versu
anoth
group
patient
receiv
etoposid
earli
introduct
etoposid
signific
variabl
improv
etoposid
appear
interfer
ebvinduc
lymphocyt
transform
suppress
format
ebv
nuclear
antigen
despit
potenti
risk
benefit
etoposid
justifi
earli
use
light
fact
even
seemingli
mild
case
may
deterior
quickli
ma
rather
uniqu
hlh
case
may
respond
quit
well
high
dose
corticosteroid
alon
one
first
report
treat
ma
associ
hlh
corticosteroid
case
seri
sjia
franc
describ
seven
children
hemorrhag
hepat
neurolog
featur
later
realiz
ma
children
treat
highdos
steroid
five
seven
sever
case
seri
similar
csa
therapi
also
becom
promin
therapi
addit
corticosteroid
ma
associ
sjia
csa
may
preferenti
inhibit
lymphocyt
target
transcript
factor
activ
variou
cytokin
csa
like
inhibit
cytokin
storm
ma
cyclophosphamid
also
use
target
lymphocyt
etoposidebas
regimen
use
ma
risk
must
weigh
care
virtual
genet
case
hlh
mani
secondari
case
treat
hsct
first
report
success
hsct
report
sever
studi
demonstr
hsct
true
hope
perman
control
diseas
essenti
studi
children
treat
follow
hsct
demonstr
similar
longterm
diseasefre
surviv
year
match
unrel
donor
transplant
match
sibl
transplant
surviv
famili
haploident
donor
transplant
mismatch
unrel
transplant
show
much
less
favor
result
longterm
diseasefre
surviv
cord
blood
transplant
success
patient
howev
overal
transplant
morbid
mortal
remain
high
pediatr
studi
show
mortal
rate
patient
death
result
pulmonari
liver
patient
respond
well
pretranspl
induct
therapi
appear
respond
best
hsct
pretranspl
condit
regimen
gener
includ
busulfan
etoposid
cyclophosphamid
busulfan
level
must
care
monitor
clonazepam
phenytoin
may
use
anticonvuls
prophylaxi
dexamethason
may
use
prevent
anaphylacticlik
symptom
mesna
use
protect
cyclophosphamideinduc
bladder
injuri
trimethoprimsulfamethoxazol
may
use
pneumocysti
prophylaxi
acyclovir
prophylaxi
acut
graft
versu
host
diseas
gvhd
appear
common
complic
posttranspl
rate
high
chronic
gvhd
rate
addit
patient
may
develop
mix
chimer
necessit
regular
donor
lymphocyt
reduc
intens
condit
experienc
transplant
center
patient
surviv
hsct
approxim
surviv
rate
unifi
thread
treatment
best
success
rate
occur
complet
remiss
achiev
rapidli
hsct
close
follow
cn
manifest
particular
concern
longterm
deficit
possibl
primari
reactiv
hlh
protocol
includ
system
treatment
dexamethason
cross
barrier
patient
persist
cerebrospin
fluid
abnorm
intrathec
therapi
methotrex
recommend
despit
fact
studi
patient
demonstr
probabl
achiev
normal
cn
symptom
roughli
equal
without
intrathec
given
devast
cognit
neurolog
development
defect
result
hlh
mani
would
argu
benefit
intrathec
therapi
justifi
potenti
risk
despit
advanc
treatment
regimen
children
hlh
undergo
hsct
due
advanc
diseas
due
rariti
hlh
short
surviv
salvag
therapi
describ
variou
case
report
larg
studi
leav
clinician
evidencebas
option
refractori
hlh
remov
cytokin
via
plasmapheresi
describ
support
patient
therapi
reach
therapeut
recombin
human
thrombopoietin
use
support
therapi
thrombocytopenia
use
monoclon
antibodi
alemtuzumab
infliximab
daclizumab
describ
variou
case
report
alemtuzumab
target
antigen
express
lymphocyt
monocyt
macrophag
dendrit
infliximab
target
tnf
daclizumab
target
use
report
addit
etanercept
tnf
inhibitor
use
success
patient
acut
lupu
hemophagocyt
variou
case
report
elabor
treatment
refractori
case
even
liver
transplant
damag
caus
unbridl
macrophag
howev
given
scarciti
literatur
subject
unclear
role
measur
play
treatment
hlh
hlh
divers
condit
mani
caus
like
underrecogn
contribut
high
morbid
mortal
earli
recognit
crucial
reason
attempt
cur
therapi
made
atg
treatment
regimen
follow
hsct
greatli
increas
surviv
devast
diseas
number
recent
studi
contribut
understand
hlh
pathophysiolog
lead
altern
treatment
option
howev
much
work
remain
rais
awar
improv
effect
treatment
regimen
